1-14 of 14
Johanna C. Bendell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

Melissa L. Johnson, Beni B. Wolf, Judy S. Wang, Alexander Philipovskiy, Geoffrey I. Shapiro, Bruno Bockorny, Wei Guo, Jinshan Shen, Kai Yu Jen, MaryBeth LeRose, Tamieka Lauz Hunter, Mahesh Padval, Oleg Schmidt-Kittler, Namrata Bhatia, Sarita Dubey, Julia Suchomel, Johanna C. Bendell, Shekeab Jauhari, Jennifer Eng-Wong, Jessica J. Lin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF8.
https://doi.org/10.1158/1535-7163.MCT-24-0466
Published: 31 December 2024
View article titled, First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Open the PDF for First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

Samuel J. Klempner, Johanna C. Bendell, Victoria Meucci Villaflor, Laura LaNiel Tenner, Stacey M. Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya F. Chaney, John H. Strickler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (11): 2240–2249.
https://doi.org/10.1158/1535-7163.MCT-21-0273
Published: 01 November 2021
View article titled, Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
Open the PDF for Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers in another window
Journal Articles

Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer

Eileen Mary O'Reilly, Judy Sing-Zan Wang, Kenneth H. Yu, Maeve Aine Lowery, Anna M. Varghese, Johanna C. Bendell, Erkut Hasan Borazanci, Hayley Estrella, Kimberly Fowler, Mariella Hoskins, Stephanie Bussen, Teresa J. Melink, Christine M. Kearns, H Toni Jun, Paul W. Maffuid, John C. Gutheil, Todd Michael Bauer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B25.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B25
Published: 01 January 2018
View article titled, Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer
Journal Articles

Abstract A194: PEGylated human IL-10 (AM0010) in advanced solid tumors

Jeffrey R. Infante, Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Deborah J. Wong, Gerald S. Falchook, Manish Patel, Shubham Pant, Melinda Whiteside, Johanna C. Bendell, Todd M. Bauer, Filip Janku, Milind Javle, Rivka Colen, Nizar Tannir, Martin Oft
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A194.
https://doi.org/10.1158/1535-7163.TARG-15-A194
Published: 01 December 2015
View article titled, Abstract A194: PEGylated human IL-10 (AM0010) in advanced solid tumors
Journal Articles

Abstract A68: Activity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR+) breast cancer cell lines and patients (pts) with genetically characterized HR+ breast cancer in a Phase I clinical trial.

Monica M. Mita, Hendrik-Tobias Arkenau, Johanna C. Bendell, Pamela N. Munster, Amit Mahipal, Jean-Pierre Delord, Luis G. Paz-Ares, Jean-Charles Soria, Shuichan Xu, Tam Tran, Tao Shi, Xiaoling Wu, Rajesh Chopra, Kristen Hege, Andrea Varga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A68.
https://doi.org/10.1158/1535-7163.TARG-13-A68
Published: 01 November 2013
View article titled, Abstract A68: Activity of the TORC 1/2 kinase inhibitor, CC-223, in hormone receptor positive (HR+) breast cancer cell lines and patients (pts) with genetically characterized HR+ breast cancer in a Phase I clinical trial.
Journal Articles

Abstract A17: ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study.

Johanna C. Bendell, Manish Patel, Jeffrey R. Infante, Carla Kurkjian, Suzanne Jones, Shubham Pant, Howard A. Burris, John D. Hainsworth, Ofir Moreno, Kathleen Moore
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A17.
https://doi.org/10.1158/1535-7163.TARG-13-A17
Published: 01 November 2013
View article titled, Abstract A17: ME-344, a novel mitochondrial oxygenase inhibitor: Results from a first-in-human Phase I study.
Journal Articles

Abstract A166: A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily (BID) in patients (pts) with advanced solid tumors.

Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante, Todd Bauer, Howard A. Burris, David R. Spigel, Denise A. Yardley, F Anthony Greco, Kent C. Shih, Dana S. Thompson, Suzanne F. Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A166.
https://doi.org/10.1158/1535-7163.TARG-13-A166
Published: 01 November 2013
View article titled, Abstract A166: A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily (BID) in patients (pts) with advanced solid tumors.
Journal Articles

Abstract A252: A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers.

Johanna C. Bendell, Anthony W. Tolcher, Suzanne F. Jones, Muralidhar Beeram, Jeffrey R. Infante, Paul Larsen, Kevin Rasor, Jennifer E. Garrus, Jinfang Li, P. Louann Cable, Christine Eberhardt, Jennifer Schreiber, Selena Rush, Kenneth W. Wood, Emma Barrett, Amita Patnaik
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A252.
https://doi.org/10.1158/1535-7163.TARG-13-A252
Published: 01 November 2013
View article titled, Abstract A252: A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers.
Journal Articles

Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors.

Johanna C. Bendell, Kyriakos Papadopoulos, Suzanne F. Jones, Emma Barrett, Kari Guthrie, Carrie L. Kass, Kevin S. Litwiler, Cheryl Napier, Amita Patnaik
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B243.
https://doi.org/10.1158/1535-7163.TARG-11-B243
Published: 12 November 2011
View article titled, Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors.
Journal Articles

Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.

Jeffrey R. Infante, Amita Patnaik, Suzanne F. Jones, Kiriakos P. Papadopoulos, Johanna C. Bendell, Drew W. Rasco, Kevin M. Bellew, Donna S. Cox, Michael G. Durante, Joohyun J. Park, Howard A. Burris, Ngocdiep T. Le, Anthony W. Tolcher
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B128.
https://doi.org/10.1158/1535-7163.TARG-11-B128
Published: 12 November 2011
View article titled, Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.
Journal Articles

Abstract C127: Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL‐305) in patients with advanced solid tumors

Huali Wu, Jeffrey R. Infante, Suzanne F. Jones, Howard A. Burris, III, Emily Chan, Vicki L. Keedy, Johanna C. Bendell, Beth A. Zamboni, Hiroshi Kodaira, Satoshi Ikeda, William C. Zamboni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C127.
https://doi.org/10.1158/1535-7163.TARG-09-C127
Published: 10 December 2009
View article titled, Abstract C127: Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL‐305) in patients with advanced solid tumors
Journal Articles

Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors

Neil Faulkner, Patricia M. LoRusso, Tina Guthrie, Jean‐Charles Soria, Ratislav Bahleda, Johanna C. Bendell, Jeffrey R. Infante, Christophe Massard, Barbara Van Leeuwen, Jean‐Francois Martini, Christian Scheffold, Howard A. Burris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C197.
https://doi.org/10.1158/1535-7163.TARG-09-C197
Published: 10 December 2009
View article titled, Abstract C197: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors
Journal Articles

Abstract C124: Pharmacokinetics and safety of sorafenib in combination with capecitabine in advanced solid tumors

Jeffrey R. Infante, Suzanne F. Jones, Johanna C. Bendell, F. Anthony Greco, Denise A. Yardley, Janet Woudenberg, Chetan D. Lathia, Cassie M. Lane, David R. Spigel, John D. Hainsworth, Howard A. Burris, III
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C124.
https://doi.org/10.1158/1535-7163.TARG-09-C124
Published: 10 December 2009
View article titled, Abstract C124: Pharmacokinetics and safety of sorafenib in combination with capecitabine in advanced solid tumors
Journal Articles

Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation

Andrew J. Wagner, Howard A. Burris, III, Johann S. de Bono, Gordon C. Jayson, Johanna C. Bendell, Carlos Gomez‐Roca, Saoirse Dolly, Ying‐Kiat Zee, Joseph A. Ware, Yibing Yan, Kathryn Mazina, Mika Derynck, Scott Holden, Jean‐Charles Soria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B137.
https://doi.org/10.1158/1535-7163.TARG-09-B137
Published: 10 December 2009
View article titled, Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation